Split the pot? Ra­dius shows its os­teo­poro­sis cards in fi­nal block­buster match with Am­gen

Ra­dius Health $RDUS has tak­en an­oth­er big leap down the fi­nal stretch of its Phase III race with Am­gen $AMGN, post­ing Phase III re­sults that show abaloparatide’s clear clin­i­cal ben­e­fit over a place­bo in treat­ing os­teo­poro­sis. But while the da­ta pro­vide a fresh ar­gu­ment in fa­vor of its near-term ap­proval at the FDA and EMA, there’s still a big ques­tion left unan­swered: Just how com­pet­i­tive will this drug be against Am­gen’s Phase III ri­val, as well as Eli Lil­ly’s ag­ing For­teo? And mean­while, the roll up to the FDA is al­so light­ing a fresh fire un­der the heat­ed de­bate over the cost of drugs, both old and new.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.